{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:39:39Z","timestamp":1773783579847,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-IgLON5 disease is a rare chronic autoimmune-mediated tauopathy, featured by the sleep disturbance. Several studies have described its clinical characteristics, however, the simultaneous occurrence of anti-IgLON5 disease and rectal cancer has not been reported. We described an unusual entity of anti-IgLON5 disease complicated with rectal cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 76-year-old man initially presented with slurred speech and limb tremors, followed by epileptic-like seizures, lethargy, and sleep apnea. IgG anti-IgLON5 antibodies were positive in both serum and cerebrospinal fluid. The patient responded well to the treatment of plasma exchange and a pulse and gradual reduction of steroids therapy. When the oral steroids started, mycophenolate mofetil was added. Two months later, the patient had bloody stools and pathological-confirmed moderately differentiated adenocarcinoma of the rectum.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Whereas sleep disturbance is the most common feature in patients with anti-IgLON5 disease, our case presented with slurred speech and limb tremors. Anti-IgLON5 disease complicated with rectal cancer is very rare. Tumor screening should be considered in patients with anti-IgLON5 disease to investigate the association between tumor and this disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-03044-y","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T06:03:03Z","timestamp":1672725783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-IgLON5 disease complicated with rectal adenocarcinoma: a case report"],"prefix":"10.1186","volume":"23","author":[{"given":"Yi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"issue":"6","key":"3044_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/s1474-4422(14)70051-1","volume":"13","author":"L Sabater","year":"2014","unstructured":"Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13(6):575\u201386. https:\/\/doi.org\/10.1016\/s1474-4422(14)70051-1.","journal-title":"Lancet Neurol"},{"issue":"4","key":"3044_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","volume":"132","author":"E Gelpi","year":"2016","unstructured":"Gelpi E, H\u00f6ftberger R, Graus F, Ling H, Holton JL, Dawson T, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016;132(4):531\u201343. https:\/\/doi.org\/10.1007\/s00401-016-1591-8.","journal-title":"Acta Neuropathol"},{"issue":"18","key":"3044_CR3","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/wnl.0000000000003887","volume":"88","author":"C Gaig","year":"2017","unstructured":"Gaig C, Graus F, Compta Y, H\u00f6gl B, Bataller L, Br\u00fcggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88(18):1736\u201343. https:\/\/doi.org\/10.1212\/wnl.0000000000003887.","journal-title":"Neurology."},{"issue":"14","key":"3044_CR4","doi-asserted-by":"publisher","first-page":"e1367","DOI":"10.1212\/wnl.0000000000012639","volume":"97","author":"C Gaig","year":"2021","unstructured":"Gaig C, Compta Y, Heidbreder A, Marti MJ, Titulaer MJ, Crijnen Y, et al. Frequency and characterization of movement disorders in anti-IgLON5 disease. Neurology. 2021;97(14):e1367\u201381. https:\/\/doi.org\/10.1212\/wnl.0000000000012639.","journal-title":"Neurology."},{"key":"3044_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","volume":"13 1","author":"L Sabater","year":"2016","unstructured":"Sabater L, Planagum\u00e0 J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation. 2016;13 1:226. https:\/\/doi.org\/10.1186\/s12974-016-0689-1.","journal-title":"J Neuroinflammation"},{"issue":"7","key":"3044_CR6","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00415-020-09924-y","volume":"267","author":"T Gr\u00fcter","year":"2020","unstructured":"Gr\u00fcter T, Behrendt V, Bien CI, Gold R, Ayzenberg I. Early immunotherapy is highly effective in IgG1\/IgG4 positive IgLON5 disease. J Neurol. 2020;267(7):2151\u20133. https:\/\/doi.org\/10.1007\/s00415-020-09924-y.","journal-title":"J Neurol"},{"key":"3044_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000577","volume":"6 4","author":"V Brunetti","year":"2019","unstructured":"Brunetti V, Della Marca G, Spagni G, Iorio R. Immunotherapy improves sleep and cognitive impairment in anti-IgLON5 encephalopathy. Neurol Neuroimmunol Neuroinflamm. 2019;6 4:e577. https:\/\/doi.org\/10.1212\/nxi.0000000000000577.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"3044_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/ane.13207","volume":"141","author":"P Cabezudo-Garc\u00eda","year":"2020","unstructured":"Cabezudo-Garc\u00eda P, Mena-V\u00e1zquez N, Estivill Torr\u00fas G, Serrano-Castro P. Response to immunotherapy in anti-IgLON5 disease: a systematic review. Acta Neurol Scand. 2020;141(4):263\u201370. https:\/\/doi.org\/10.1111\/ane.13207.","journal-title":"Acta Neurol Scand"},{"key":"3044_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1212\/nxi.0000000000000605","volume":"6","author":"C Gaig","year":"2019","unstructured":"Gaig C, Ercilla G, Daura X, Ezquerra M, Fern\u00e1ndez-Santiago R, Palou E, et al. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurol Neuroimmunol Neuroinflamm. 2019;6:6. https:\/\/doi.org\/10.1212\/nxi.0000000000000605.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3044_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000385","volume":"4 5","author":"JA Honorat","year":"2017","unstructured":"Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4 5:e385. https:\/\/doi.org\/10.1212\/nxi.0000000000000385.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3044_CR11","doi-asserted-by":"publisher","first-page":"6290261","DOI":"10.1155\/2021\/6290261","volume":"2021","author":"W Chen","year":"2021","unstructured":"Chen W, Huang J, Xiong J, Fu P, Chen C, Liu Y, et al. Identification of a tumor microenvironment-related gene signature indicative of disease prognosis and treatment response in Colon Cancer. Oxidative Med Cell Longev. 2021;2021:6290261. https:\/\/doi.org\/10.1155\/2021\/6290261.","journal-title":"Oxidative Med Cell Longev"},{"key":"3044_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1212\/nxi.0000000000001014","volume":"8","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, Antoine JG, Desestret V, Dubey D, et al. Updated diagnostic criteria for Paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8:4. https:\/\/doi.org\/10.1212\/nxi.0000000000001014.","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03044-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-03044-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03044-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T06:03:19Z","timestamp":1672725799000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-03044-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3044"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-03044-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the amended Declaration of Helsinki and it was approved by the Ethics committee of Medical Science Research, Affiliated Hospital of Jining Medical University (2022C208).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This case report obtained written informed patient consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}